Thank you for this article about an experimental method to increase the expression of Nrf2, a transcription factor that activates the ARE (antioxidant response element) in the nucleus, which “drives the expression of detoxifying and antioxidant genes.” It’s useful to remember that S1R agonism (such as with (+)-pentazocine) also increases the expression of Nrf2. I would think Anavex 2-73 would also have such an effect, as it is a potent S1R agonist. Refer to ‘Targeting S1R: A Promising Strategy in the treatment of Parkinson’s Disease’, Neurochem Res 2023, May 31: 1-11.
An interesting tidbit from my notes on this subject: “When Nrf2 is activated, it enters the nucleus and turns on several hundred genes, known collectively as “survival genes.” This, in turn, initiates the production of several of your body’s own enzymes that fight free radicles. These include catalase, glutathione, and superoxide dismutase. These are much more effective than exogenous antioxidants at getting rid of free radicles. Nrf2 is known as the “master regulator” of our body’s antioxidant response.
News 
Market Data 
Discover 
